Investors eyeing a purchase of Aclaris Therapeutics Inc (ACRS) shares, but tentative about paying the going market price of 9.86/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the February ...

Aclaris Therapeutics, Inc. (NASDAQ:ACRS Get Rating) Stock analysts at Jefferies Financial Group boosted their FY2025 earnings per share estimates for Aclaris Therapeutics in a note issued to investors on Monday, March 6th. Jefferies Financial Group analyst R. Song now expects that ...

Aclaris Therapeutics (NASDAQ:ACRS Get Rating) had its target price decreased by The Goldman Sachs Group from $25.00 to $21.00 in a report released on Tuesday , Benzinga reports. The Goldman Sachs Group currently has a buy rating on the biotechnology companys stock. Several other research analysts ...

Gainers Unicycive Therapeutics, Inc. (NASDAQ: UNCY) shares surged 159% to $1.27 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch Renazorb. read more...

WAYNE, Pa., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today is providing a corporate outlook for 2023. 2023 is setting up to be an incredibly ...